Literature DB >> 17700106

Dupuytren's disease: history, diagnosis, and treatment.

Robert B Shaw1, Alphonsus K S Chong, Andrew Zhang, Vincent R Hentz, James Chang.   

Abstract

LEARNING
OBJECTIVES: After studying this article, the participant should be able to: 1. Describe the clinical features of the disease. 2. Describe the pathoanatomical structures in Dupuytren's disease. 3. Outline the various factors associated with Dupuytren's disease. 4. Describe the modalities for surgical and nonsurgical treatment of the condition. 5. Outline recent biomolecular knowledge about the basis of Dupuytren's disease.
SUMMARY: Dupuytren's disease is characterized by nodule formation and contracture of the palmar fascia, resulting in flexion deformity of the fingers and loss of hand function. The authors review the historical background, clinical features, and current therapy of Dupuytren's disease; preview treatment innovations; and present molecular data related to Dupuytren's disease. These new findings may improve screening for Dupuytren's disease and provide a better understanding of the disease's pathogenesis.

Entities:  

Mesh:

Year:  2007        PMID: 17700106     DOI: 10.1097/01.prs.0000278455.63546.03

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  36 in total

1.  Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren's disease.

Authors:  R Arora; P Kaiser; T-J Kastenberger; G Schmiedle; S Erhart; M Gabl
Journal:  Oper Orthop Traumatol       Date:  2015-12-18       Impact factor: 1.154

2.  Surgical complications associated with fasciectomy for dupuytren's disease: a 20-year review of the English literature.

Authors:  Keith Denkler
Journal:  Eplasty       Date:  2010-01-27

3.  Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture.

Authors:  Latha Satish; David B O'Gorman; Sandra Johnson; Christina Raykha; Bing Siang Gan; James H-C Wang; Sandeep Kathju
Journal:  Cell Stress Chaperones       Date:  2013-01-06       Impact factor: 3.667

4.  Operative trends and physician treatment costs associated with Dupuytren's disease in Canada.

Authors:  Wendy Liu; David B O'Gorman; Bing Siang Gan
Journal:  Can J Plast Surg       Date:  2013

Review 5.  Outcomes of Surgery in Peyronie's Disease Following Intralesional Collagenase Clostridium Histolyticum Injections.

Authors:  Mahdi Bazzi; Marcus L Jamil; Ali A Dabaja
Journal:  Curr Urol Rep       Date:  2019-06-14       Impact factor: 3.092

Review 6.  The Genetic Basis of Peyronie Disease: A Review.

Authors:  Amin S Herati; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-01-08

7.  Screening of candidate genes in fibroblasts derived from patients with Dupuytren's contracture using bioinformatics analysis.

Authors:  Haoyu Liu; Weitian Yin; Biao Liu; Yan Liu; Baofeng Guo; Zhuang Wei
Journal:  Rheumatol Int       Date:  2015-05-12       Impact factor: 2.631

8.  Molecular mechanisms and treatment strategies for Dupuytren's disease.

Authors:  David B O'Gorman; Linda Vi; Bing Siang Gan
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

9.  Percutaneous fasciotomy for the treatment of Dupuytren's disease-a systematic review.

Authors:  Saoussen Salhi; Etienne Cardin-Langlois; Mario Luc
Journal:  Hand (N Y)       Date:  2011-08-19

10.  Modified percutaneous needle aponeurotomy for the treatment of dupuytren's contracture: early results and complications.

Authors:  Fernando A Herrera; Scott Mitchell; Mark Elzik; Jason Roostaeian; Prosper Benhaim
Journal:  Hand (N Y)       Date:  2015-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.